US 12,152,032 B2
Heterocyclic compounds and uses thereof
Alfredo C. Castro, Woburn, MA (US); Catherine A. Evans, Somerville, MA (US); Somarajannair Janardanannair, Woburn, MA (US); Andre Lescarbeau, Somerville, MA (US); Tao Liu, Wellesley, MA (US); and Martin R. Tremblay, Melrose, MA (US)
Assigned to Infinity Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Infinity Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Mar. 15, 2021, as Appl. No. 17/202,195.
Application 15/794,816 is a division of application No. 14/695,699, filed on Apr. 24, 2015, granted, now 9,828,377, issued on Nov. 28, 2017.
Application 17/202,195 is a continuation of application No. 16/417,420, filed on May 20, 2019, abandoned.
Application 16/417,420 is a continuation of application No. 15/794,816, filed on Oct. 26, 2017, granted, now 10,329,299, issued on Jun. 25, 2019.
Application 14/695,699 is a continuation of application No. 14/506,429, filed on Oct. 3, 2014, granted, now 9,359,365, issued on Jun. 7, 2016.
Claims priority of provisional application 61/938,026, filed on Feb. 10, 2014.
Claims priority of provisional application 61/888,958, filed on Oct. 9, 2013.
Claims priority of provisional application 61/887,259, filed on Oct. 4, 2013.
Prior Publication US 2022/0372038 A1, Nov. 24, 2022
Int. Cl. C07D 487/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01)] 17 Claims
 
1. A compound of Formula (A′):

OG Complex Work Unit Chemistry
wherein:
R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —COR2—COOR3, or —CONR4R5;
B is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —COR2, —COOR3,—CONR4R5, or —Si(R6)3;
wherein R2, R3, R4 R5, and R6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
Wd is heteroaryl, cycloalkyl, heterocycloalkyl, or aryl; and
X is CR1a or N;
wherein R1a is hydrogen, halo, alkyl, alkenyl, alkynyl, or CN;
wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more halo, OH, alkoxy, NH2, NH(alkyl), N(alkyl)2, COH, CO(alkyl), COOH, COO(alkyl), CONH2, CONH(alkyl), CON(alkyl)2, S(O)(alkyl), S(O)2(alkyl), cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
wherein each cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more halo, alkyl, alkenyl, alkynyl, OH, alkoxy, oxo, NH2, NH(alkyl), N(alkyl)2, COH, CO(alkyl), COOH, COO(alkyl), CONH2, CONH(alkyl), CON(alkyl)2, S(O)(alkyl), or S(O)2(alkyl);
wherein in Formula (A′), when X is CH, B is unsubstituted phenyl, and Wd is

OG Complex Work Unit Chemistry
then R1 is not phenyl;
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, mixture of stereoisomers, prodrug, or isotopically labeled derivative thereof.